COVID-19 Governance Licensing Pharmaceutical Industry 
Bill of Health
AUGUST 29, 2022
On October 8, 2020, Moderna, the maker of one of the first mRNA-based vaccines for COVID-19 and the recipient of billions of dollars of U.S. government funding, announced that it felt “a special obligation … to use our resources to bring this pandemic to an end as quickly as possible.” Tesla and Toyota) to software (e.g,
Bill of Health
MAY 5, 2023
The COVID-19 crisis demonstrated how the need for protecting and incentivizing innovation clashed with the need to make products widely available. To solve this tension, the Commission recognizes that patent law already offers a solution: compulsory licensing. This effort and the proposed legislation do not come as a surprise.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bill of Health
SEPTEMBER 28, 2023
By Nikhil Chaudhry and Reshma Ramachandran Earlier this month, the Department of Health and Human Services announced that it had successfully included a reasonable pricing provision in a $326M investment contract with Regeneron for development of a next generation monoclonal antibody therapy for COVID-19. pharmaceutical market.
Hall Render
APRIL 21, 2023
health-tech startup MemoryWell pivots, eyes new funding to roll out software for insurers Department of Veterans Affairs health system kicks off multiyear Greater Washington expansion Georgetown to open Southeast D.C.
SQA
FEBRUARY 26, 2024
This standard is a globally recognized standard that provides guidelines for the governance and management of AI technologies. It provides a practical guide for the pharmaceutical industry on how to implement PACs within the framework of an effective Pharmaceutical Quality System (PQS) and in alignment with ICH quality guidelines.
Expert insights. Personalized for you.
362 
Let's personalize your content